Evidence map›Paper›PMID 32117811›Full record

ArticleFrontiers in cellular and infection microbiology2020

Amplification of Replication Competent HIV-1 by Adoptive Transfer of Human Cells From Infected Humanized Mice.

Hang Su, Sruthi Sravanam, Santhi Gorantla, Rafal Kaminski, Kamel Khalili, Larisa Poluektova, Howard E Gendelman, Prasanta K Dash

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Recovery of Latent HIV-1 from Brain Tissue by Adoptive Cell Transfer in Virally Suppressed Humanized Mice.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021
    Article
  7. Review
  8. HIV-1 cure strategies: why CRISPR?Expert opinion on biological therapy · 2021
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hang SuDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
Sruthi SravanamDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
Santhi GorantlaDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
Rafal KaminskiDepartment of Neuroscience, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Kamel KhaliliDepartment of Neuroscience, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Larisa PoluektovaDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
Prasanta K DashDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
University of Nebraska Medical Center · USTemple University · US

Funding

Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BUCH, SHILPA J., FOX, HOWARD S · 2000 to 2021
$37.7M
Viral Gene Editing and Bioinformatics Core for Institution # 269291P30MH092177 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI SHOHREH AMINI · 2011 to 2026
$24.9M
Pharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2010 to 2019
$16.8M
Neuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3M
HIV/COCAINE NEUROTOXICITY IN FEMALESR01DA013137 · NIDA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BOOZE, ROSEMARIE M, MACTUTUS, CHARLES F. · 2000 to 2021
$7.7M
Project 3 Dysregulation of metabolic communication of oligodendrocytes and neurons by cocaine and TatP01DA037830 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI KHALILI, KAMEL · 2015 to 2019
$7.4M
Gene editing strategies to target HIV for elimination in periphery and brainR01MH110360 · NIMH · DREXEL UNIVERSITY · PI Ilker Kudret Sariyer, Brian Wigdahl · 2016 to 2026
$7.3M
Nanomedicine and NeuroAIDSR01NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 1997 to 2017
$5.7M
Combined Molecular Excision Therapy (CMET) for Eliminating HIV-1R01MH115860 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2017 to 2021
$3.5M
Center for Humanized MiceR24OD018546 · OD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GORANTLA, SANTHI, POLUEKTOVA, LARISA Y · 2014 to 2017
$3.2M
Nanotechnology Based Gene Editing to Eradicate HIV Brain Reservoir in Drug AbusersR01DA042706 · NIDA · FLORIDA INTERNATIONAL UNIVERSITY · PI KHALILI, KAMEL, NAIR, MADHAVAN P. · 2016 to 2020
$3.2M
SMART HANDR01AG043540 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E, POLUEKTOVA, LARISA Y · 2013 to 2017
$3.1M
NIA NIH HHS R01 AG043540NIDA NIH HHS P01 DA028555NIDA NIH HHS P01 DA037830NIDA NIH HHS R01 DA013137NIDA NIH HHS R01 DA042706NIH HHS R24 OD018546NIMH NIH HHS P30 MH062261NIMH NIH HHS P30 MH092177NIMH NIH HHS R01 MH110360NIMH NIH HHS R01 MH115860NINDS NIH HHS R01 NS034239NINDS NIH HHS R01 NS036126
6 · The paper itself

Abstract

Detection of latent human immunodeficiency virus type 1 (HIV-1) in "putative" infectious reservoirs is required for determining treatment efficiency and for viral elimination strategies. Such tests require induction of replication competent provirus and quantitative testing of viral load for validation. Recently, humanized mice were employed in the development of such tests by employing a murine viral outgrowth assay (mVOA). Here blood cells were recovered from virus infected antiretroviral therapy suppressed patients. These cells were adoptively transferred to uninfected humanized mice where replication competent virus was recovered. Prior reports supported the notion that an mVOA assay provides greater sensitivity than cell culture-based quantitative VOA tests for detection of latent virus. In the current study, the mVOA assays was adapted using donor human hematopoietic stem cells-reconstituted mice to affirm research into HIV-1 elimination. We simulated an antiretroviral therapy (ART)-treated virus-infected human by maintaining the infected humanized mice under suppressive treatment. This was operative prior to human cell adoptive transfers. Replication-competent HIV-1 was easily detected in recipient animals from donors with undetectable virus in plasma. Moreover, when the assay was used to investigate viral presence in tissue reservoirs, quantitative endpoints were determined in "putative" viral reservoirs not possible in human sample analyses. We conclude that adoptive transfer of cells between humanized mice is a sensitive and specific assay system for detection of replication competent latent HIV-1.

Indexed as

HIV-1HIV InfectionsAdoptive TransferAnimalsCD4-Positive T-LymphocytesHumansMiceViral LoadVirus LatencyVirus Replicationadoptive transfersHIV-1 infectionhumanized micelymphoid tissueviral latencyviral outgrowth assaysviral reservoirs

Identifiers

PMID32117811
PMCPMC7026001
OpenAlexW3005596950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.